Alpha 1 Antitrypsin Deficiency Treatment Market Report 2025 (Global Edition)

Global Alpha 1 Antitrypsin Deficiency Treatment Market Report 2024 Market Size Split by Treatment Type (Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy, Others), by Route of Admi...

Alpha 1 Antitrypsin Deficiency Treatment Market Report Description

We have various report editions of Alpha 1 Antitrypsin Deficiency Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape Of The Alpha-1 Antitrypsin Deficiency Treatment Market

The competitive landscape of the alpha-1 antitrypsin deficiency treatment market is dynamic, characterized by key players investing in research and development to introduce innovative therapies. Robust strategic collaborations, mergers, and acquisitions augment market presence. Ongoing efforts to address unmet patient needs and regulatory compliance contribute to the competitive edge, shaping a vibrant and evolving marketplace.

Alpha-1 Antitrypsin Deficiency Treatment Industry News

In May 2022, Kamada Ltd announced the expansion of its pivotal Phase 3 clinical trial for inhaled Alpha-1 Antitrypsin (AAT) across six additional clinical sites in Europe. Concurrently, the Data Safety Monitoring Board (DSMB) provided a favorable recommendation to continue the trial without modification, affirming its safety and progress.

Source-www.kamada.com/news/kamada-announces-expansion-of-pivotal-phase-3-clinical-trial-of-inhaled-aat-to-additional-six-clinical-sites-across-europe-and-positive-recommendation-by-dsmb-to-continue-the-trial-without-modificati/

Top Companies Market Share in Alpha 1 Antitrypsin Deficiency Treatment Industry: (In no particular order of Rank)

• Takeda Pharmaceutical Company Limited
• Kamada Pharmaceuticals
• AstraZeneca
• Pfizer Inc.
• LFB Biomedicaments S.A.
• Grifols S.A.
• CSL Behring
• GlaxoSmithKline PLC
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Ltd.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

In terms of revenue, the North America Alpha 1 Antitrypsin Deficiency Treatment Market share was 40% of the total marke

According to Cognitive Market Research, North America dominated the market in 2023 and accounted for around 40% of the global revenue. Established pharmaceutical collaborations and research initiatives contribute to a concentrated market presence. The region's proactive regulatory environment fosters swift product approvals, fuelling a consistent revenue stream. Additionally, heightened disease awareness and widespread diagnostic capabilities bolster treatment rates. North America's leadership is sustained by a synergistic interplay of factors, creating a lucrative landscape for sustained market dominance by revenue.

Asia-Pacific is the fastest-growing region. The region's large population base, combined with an increasing prevalence of respiratory disorders, contributes to a burgeoning patient pool. Strategic collaborations between regional and international healthcare entities stimulate the market's rapid growth. Innovative therapies tailored to the region's genetic diversity amplify treatment efficacy, further fuelling sales. As healthcare infrastructures advance, and awareness campaigns intensify, Asia-Pacific stands poised for dynamic and sustained growth in the alpha-1 antitrypsin deficiency treatment market.

The current report Scope analyzes Alpha 1 Antitrypsin Deficiency Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Alpha 1 Antitrypsin Deficiency Treatment

According to Cognitive Market Research, the global alpha 1 antitrypsin deficiency treatment market size was estimated at USD 2951.2 Million out of which North America held the major market of around 40% of the global revenue with a market size of USD 1180.48 million in 2023 and will grow at a compound annual growth rate (CAGR) of 12.0% from 2023 to 2030. Sales of alpha-1 antitrypsin deficiency treatment are poised for growth in North America due to the region's advanced healthcare infrastructure and early adoption of cutting-edge therapies. Heightened investments in genetic research contribute to personalized treatment options, further enhancing market expansion in North America. Augmentation therapy in alpha-1 antitrypsin deficiency treatment, anticipates a surge in sales in North America. Fuelled by advanced healthcare infrastructure and proactive regulatory measures, its prominence is expected to grow, addressing the escalating demand for innovative therapies in managing alpha-1 antitrypsin deficiency effectively.

• According to Cognitive Market Research, the US had a major share in the alpha 1 antitrypsin deficiency treatments market with a market size of USD 931.40 million in 2023 and is projected to grow at a CAGR of 11.8% during the forecast period. Sales of alpha-1 antitrypsin deficiency treatment are set to increase in the U.S. due to robust healthcare infrastructure, widespread disease awareness campaigns, and strategic collaborations driving innovation and treatment accessibility.
• The Canada alpha 1 antitrypsin deficiency treatments market had a market share of USD 141.66 million in 2023 and is projected to grow at a CAGR of 12.8% during the forecast period. In Canada, alpha-1 antitrypsin deficiency treatment sales will rise with increasing emphasis on personalized medicine, advancements in genetic testing, and the proactive healthcare system promoting early diagnosis and intervention.
• The Mexico alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 12.5% during the forecast period with a market size of USD 107.42 million in 2023.

Europe Alpha 1 Antitrypsin Deficiency Treatment

According to Cognitive Market Research, with a market value of USD 2951.2 million in 2023 and projected to expand at a compound annual growth rate (CAGR) of 13.80% from 2023 to 2030, Europe accounted for a share of around 30% of the global market size of USD 885.36 million. In Europe the treatment, for alpha 1 antitrypsin deficiency is experiencing an increase in sales. This growth is fuelled by the regions focus on testing and personalized medicine. Additionally there is a growing awareness of the disease and proactive government initiatives that encourage diagnosis and treatment which in turn boosts the market for these treatments. Inhalation, as a favoured route of administration, foresees sales escalation in the European region. Propelled by a network of specialty clinics, collaborative research endeavours, and an emphasis on patient-centric healthcare, inhalation-based therapies are positioned for sustained growth in catering to alpha-1 antitrypsin deficiency treatment demands.

• According to Cognitive Market Research, the Germany alpha 1 antitrypsin deficiency treatments market size was valued at USD 175.30 million in 2023 and is projected to grow at a CAGR of 12.5% during the forecast period. Alpha-1 antitrypsin deficiency treatment sales in Germany will surge due to a robust healthcare ecosystem, investments in research, and a progressive regulatory environment fostering rapid product approvals and market expansion.
• The United Kingdom alpha 1 antitrypsin deficiency treatments market had a market share of USD 148.74 million in 2023 and is projected to grow at a CAGR of 13.1% during the forecast period. Sales of alpha-1 antitrypsin deficiency treatment are poised for growth in the UK, driven by a commitment to genetic research, increasing disease awareness, and specialized healthcare facilities promoting comprehensive patient care.
• The France alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 11.5% during the forecast period with a market size of USD 81.45 million in 2023.
• The Italy alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 11.7% during the forecast period with a market size of USD 76.14 million in 2023.
• The Russia alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 11.3% during the forecast period with a market size of USD 137.23 million in 2023.
• The Spain alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 11.4% during the forecast period with a market size of USD 72.60 million in 2023.
• The Portugal alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 12.1% during the forecast period with a market size of USD 18.59 million in 2023.
• The Luxembourg alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 12.4% during the forecast period with a market size of USD 27.45 million in 2023.
• The Greece alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 12.6% during the forecast period with a market size of USD 10.62 million in 2023.
• The Rest of Europe alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 11.0% during the forecast period with a market size of USD 137.23 million in 2023.

Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment

According to Cognitive Market Research, the global Alpha 1 antitrypsin deficiency treatment market size was estimated at USD 2951.2 Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 678.78 million in 2023 and will grow at a compound annual growth rate (CAGR) of 15.8% from 2023 to 2030. The rise in preventive healthcare practices, coupled with awareness campaigns, amplifies diagnosis rates and drives market growth. As healthcare infrastructures advance, Asia-Pacific stands as a dynamic hub for alpha-1 antitrypsin deficiency treatment sales expansion. Hospitals, as pivotal end-users, anticipate heightened sales in the Asia-Pacific region. Driven by expanding healthcare accessibility and a burgeoning prevalence of respiratory disorders, hospitals play a central role in fostering alpha-1 antitrypsin deficiency treatment, contributing to the region's dynamic and evolving healthcare landscape.

• According to Cognitive Market Research, the China alpha 1 antitrypsin deficiency treatments market size was valued at USD 305.45 million in 2023 and is projected to grow at a CAGR of 15.3% during the forecast period. Alpha-1 antitrypsin deficiency treatment sales in China will soar with expanding healthcare accessibility, a growing population, and strategic collaborations fostering the development of innovative therapies tailored to diverse genetic profiles. 
• The India alpha 1 antitrypsin deficiency treatments market had a market share of USD 81.45 million in 2023 and is projected to grow at a CAGR of 17.6% during the forecast period. In India, alpha-1 antitrypsin deficiency treatment sales will rise due to increasing disease awareness, a burgeoning prevalence of respiratory disorders, and a proactive healthcare approach emphasizing early diagnosis and personalized treatment.
• The Japan alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 14.3% during the forecast period with a market size of USD 93.67 million in 2023.
• The South Korea alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 14.9% during the forecast period with a market size of USD 14.9 million in 2023.
• The Australia alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 15.5% during the forecast period with a market size of USD 35.30 million in 2023.
• The South East Asia alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 16.8% during the forecast period with a market size of USD 46.84 million in 2023.
• The Rest of Asia Pacific alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 15.6% during the forecast period with a market size of USD 48.19 million in 2023.

South America Alpha 1 Antitrypsin Deficiency Treatment

According to Cognitive Market Research, the global Alpha 1 antitrypsin deficiency treatments market size was estimated at USD 2951.2 Million out of which Latin America market of around 5% of the global revenue with a market size of USD 147.56 million in 2023 and will grow at a compound annual growth rate (CAGR) of 13.2% from 2023 to 2030. In Latin America the sales of treatments, for alpha 1 antitrypsin deficiency are increasing, primarily driven by a growing emphasis on raising awareness about the disease and enhancing healthcare infrastructure. As Latin America works towards reducing healthcare disparities and prioritizing health there is a surge in the demand, for alpha 1 antitrypsin deficiency treatment. Augmentation therapy envisions a surge in sales within the Latin America region. Fuelled by a growing emphasis on disease awareness, improving healthcare infrastructure, and strategic collaborations, augmentation therapy stands poised to address the increasing demand for innovative solutions in managing alpha-1 antitrypsin deficiency effectively.

• According to Cognitive Market Research, the Brazil alpha 1 antitrypsin deficiency treatments market size was valued at USD 63.16 million in 2023 and is projected to grow at a CAGR of 13.8% during the forecast period. Alpha-1 antitrypsin deficiency treatment sales in Brazil will surge due to a focus on healthcare infrastructure, genetic diversity necessitating tailored treatments, and collaborations propelling innovative therapies in the market. 
• The Argentina alpha 1 antitrypsin deficiency treatments market had a market share of USD 24.79 million in 2023 and is projected to grow at a CAGR of 14.1% during the forecast period. In Argentina, alpha-1 antitrypsin deficiency treatment sales will rise with increasing disease awareness, a growing demand for specialized care, and strategic partnerships enhancing treatment accessibility and options.
• The Colombia alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 13.0% during the forecast period with a market size of USD 13.13 million in 2023.
• The Peru alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 13.4% during the forecast period with a market size of USD 12.10 million in 2023.
• The Chile alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 13.5% during the forecast period with a market size of USD 10.62 million in 2023.
• The Rest of Latin America alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 12.3% during the forecast period with a market size of USD 23.76 million in 2023.

Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment

According to Cognitive Market Research, the global Alpha 1 antitrypsin deficiency treatment market size was estimated at USD 2951.2 Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 59.02 million in 2023 and will grow at a compound annual growth rate (CAGR) of 13.5% from 2023 to 2030. In the Middle East and Africa (MEA), the sales outlook for alpha-1 antitrypsin deficiency treatment is optimistic, driven by a rising focus on specialized clinics and a burgeoning prevalence of respiratory disorders. Inhalation, as a preferred route of administration, foresees an upswing in sales within the MEA region. A burgeoning commitment to specialized clinics, collaborative research initiatives, and advancements in healthcare infrastructure positions inhalation-based therapies for sustained growth in addressing alpha-1 antitrypsin deficiency treatment needs effectively.

• According to Cognitive Market Research, the GCC Countries alpha 1 antitrypsin deficiency treatments market size was valued at USD 25.26 million in 2023 and is projected to grow at a CAGR of 14.3% during the forecast period. Alpha-1 antitrypsin deficiency treatment sales in GCC countries will increase due to rising healthcare investments, a focus on specialized clinics, and genetic diversity driving demand for tailored treatment options.
• The South Africa alpha 1 antitrypsin deficiency treatments market had a market share of USD 9.33 million in 2023 and is projected to grow at a CAGR of 14.5% during the forecast period. In South Africa, alpha-1 antitrypsin deficiency treatment sales will rise with advancing healthcare infrastructure, increasing disease awareness, and collaborative efforts fostering the development of innovative therapies for varied patient needs.
• The Egypt alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 13.8% during the forecast period with a market size of USD 6.20 million in 2023.
• The Turkey alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 13.0% during the forecast period with a market size of USD 5.08 million in 2023.
• The Nigeria alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 12.6% during the forecast period with a market size of USD 6.20 million in 2023.
• The Rest of MEA alpha 1 antitrypsin deficiency treatments market is projected to witness growth at a CAGR of 12.5% during the forecast period with a market size of USD 6.96 million in 2023.

Alpha 1 Antitrypsin Deficiency Treatment Market Analysis

Alpha 1 Antitrypsin Deficiency Treatment Market Treatment Type Segment Analysis

According to Cognitive Market Research, augmentation therapy held the major market share over the forecast period. Sales in this segment are driven by the critical need for therapies addressing the root cause of alpha-1 antitrypsin deficiency, positioning augmentation therapy as a cornerstone in the market. The continued emphasis on research and development further propels this treatment's dominance, maintaining its leading position in sales.

Bronchodilator is the fastest-growing category over the forecast period. The market's responsiveness to bronchodilators underscores a growing recognition of the importance of symptom management alongside targeted therapies. Sales growth in this segment is fuelled by an increasing emphasis on holistic patient care, creating opportunities for innovative bronchodilator formulations that resonate with evolving market dynamics and contribute to overall market expansion.

• Augmentation Therapy
• Bronchodilator
• Corticosteroids
• Oxygen Therapy
• Others

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Alpha 1 Antitrypsin Deficiency Treatment Industry. Request a Free Sample PDF!

Alpha 1 Antitrypsin Deficiency Treatment Market Route of Administration Segment Analysis

According to Cognitive Market Research, inhalation hold a prominent market share. The ease of administration and targeted delivery to the respiratory system contribute to sustained sales, reflecting the preference for inhalation routes among healthcare providers and patients alike. The market's reliance on inhalation underscores its reliability and patient-friendly attributes, fostering a competitive edge that propels this category as a cornerstone in sales within the alpha-1 antitrypsin deficiency treatment landscape.

Parenteral is the fastest-growing category over the forecast period. The rising prominence of parenteral routes, involving injections, is driven by advancements in formulations that enhance efficacy and patient convenience. This growth aligns with a broader trend in the market, emphasizing the development of innovative delivery methods. The forecasted surge in sales for parenteral administration underscores a strategic response to evolving patient needs and market demands, positioning it as a frontrunner in the competitive landscape.

• Parenteral
• Inhalation
• Oral

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Alpha 1 Antitrypsin Deficiency Treatment End-User Segment Analysis

According to Cognitive Market Research, hospitals hold a prominent market share. The established trust in hospital settings, coupled with the availability of comprehensive medical facilities, contributes to sustained sales. Patient referrals and treatment initiation in hospitals play a pivotal role in maintaining this market dominance. The reliability associated with hospital-based care enhances sales, reinforcing hospitals as key contributors to the overall success of the alpha-1 antitrypsin deficiency treatment market.

Speciality clinics are the fastest-growing category over the forecast period. Sales growth in this segment is propelled by an increasing emphasis on tailored treatment plans and a comprehensive approach to managing alpha-1 antitrypsin deficiency. The forecasted surge in specialty clinic utilization underscores a paradigm shift in healthcare delivery, positioning it as a dynamic and rapidly expanding segment within the alpha-1 antitrypsin deficiency treatment market.

• Specialty Clinics
• Hospitals
• Pharmacies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion